For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Watch out, the MCEDs are coming
+Opinion
In print
Watch out, the MCEDs are coming
Wednesday 8 February 2023, 12:07 PM

New blood tests promise broad screening for cancer [Image: Testalize.me on Unsplash]
Jim Vause finds there is good news and bad in the development of multi-cancer early detection tests
As for commercial drive, the global multicancer early detection market was valued at US$791.58 million in 2021
It’s like something out of the Jet
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
- Multi Cancer Early Detection Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Gene Panel, LDT & Others), By End-use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2022 – 2030. Available at https://tinyurl.com/4978tukk
- Galleri by Grail www.galleri.com
- Screening to Improve Health in New Zealand: Criteria to assess screening programmes, April, 2003. Available online at https://tinyurl.com/7wpw7np9